{"ok":true,"entity":{"id":"edwards-lifesciences","name":"Edwards Lifesciences","entityType":"company","officialName":"Edwards Lifesciences Corporation","canonicalName":"Edwards Lifesciences","displayName":"Edwards Lifesciences","category":"構造的心疾患（心臓弁）医療機器企業","shortDescription":"カリフォルニア州アーバインに本社を置く、経カテーテル心臓弁（TAVR）、僧帽弁・三尖弁治療、外科用弁、心不全管理を手がける医療機器企業で、NYSE上場（EW）。2026年第2四半期の売上高は17億4,000万ドル（前年同期比13.6%増）。2026年1月に裁判所がFTCによるJenaValve買収差止めを認め、同社は買収しないと表明した（2026年10月時点）。","primaryCluster":"medical-device","parentEntity":null,"verificationStatus":"draft","website":"https://www.edwards.com/","updatedAt":"2026-10-13T05:36:43.320Z","secondaryClusters":[],"alias":["エドワーズ・ライフサイエンシズ","エドワーズライフサイエンス"],"searchKeywords":["Edwards Lifesciences","エドワーズ","TAVR","SAPIEN","PASCAL","心臓弁","構造的心疾患","アーバイン"]},"referenceIndex":["P-01-001","P-02-001","P-04-001","P-05-001","P-06-001"]}